Participants retain all right, title, and interest in their entries and underlying intellectual property, including source code, models, model weights, datasets, inventions, methods, documentation, images, and know-how, subject to any third-party licenses they use. Except for the license below, participation in the competition and submission of materials do not transfer ownership of that intellectual property to The Open Source Vision Foundation (OpenCV) or Amazon Web Services (AWS).
By submitting any proposal, report, presentation, or video in connection with the competition (collectively, “Submitted Materials”), each participant represents that it has the necessary rights and grants OpenCV and AWS, each independently, a perpetual, irrevocable (to the fullest extent permitted by law), worldwide, royalty-free, fully paid-up, non-exclusive, transferable, and sublicensable license to use, reproduce, host, store, edit, modify, adapt, translate, create derivative works from, publish, distribute, transmit, publicly display, publicly perform, promote, and otherwise use the Submitted Materials, in whole or in part, in any media now known or later developed, for any lawful commercial or noncommercial purpose, without further notice, approval, attribution, or compensation.
The license applies only to the Submitted Materials themselves. It does not grant rights to access, distribute, or use private source code, model weights, datasets, credentials, confidential materials, or other underlying project assets merely referenced, linked to, described, depicted, or demonstrated in the Submitted Materials, unless those materials are themselves included in a submission and the participant has the right to grant that license.
Personal data may be processed and shared among the contest administrator, OpenCV, and AWS only as reasonably necessary to administer the competition, verify eligibility, communicate with participants, and deliver benefits or prizes. Any use of participant data for unrelated marketing requires a separate, informed opt-in.